IDEAYA CEO proposes sale of shares valued at $8.8M

The stated sales will include cashless option exercises occurring within three months of the filing date.

Rhea-AI Filing Summary

IDEAYA Biosciences, Inc. CEO Yujiro Hata reported a proposed sale of 230,316 common shares, with an aggregate market value of $8,804,981 and an approximate sale date of October 6, 2026. J.P. Morgan Securities LLC is listed as broker, and Nasdaq as the exchange. The stated sales will include cashless option exercises occurring within three months of the filing date.

Key Figures

Common shares proposed for sale: 230,316 shares Aggregate market value: $8,804,981 Shares outstanding: 96,489,484 shares +1 more

4 metrics

Common shares proposed for sale 230,316 shares Approximate sale date: October 6, 2026

Aggregate market value $8,804,981 Securities listed for sale

Shares outstanding 96,489,484 shares Share-count figure shown with the sale details

Cashless option exercise period 3 months Period stated for the cashless option exercises

Key Terms

Cashless Option Exercises, aggregate market value, Rule 144

3 terms

Cashless Option Exercises technical

"sales under this filing will include Cashless Option Exercises"

aggregate market value financial

"Aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IDEAYA (IDYA) shares is CEO Yujiro Hata proposing to sell?

Yujiro Hata's notice lists 230,316 IDEAYA common shares for sale, with an aggregate market value of $8,804,981 and an approximate sale date of October 6, 2026.

What does the IDEAYA (IDYA) notice say about cashless option exercises?

Sales under the notice will include cashless option exercises that will occur within three months from the filing date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 04:13 PM Accepted by SEC EDGAR 10/06/2026 - 04:13 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001649119
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IDEAYA Biosciences, Inc.
SEC File Number	001-38915
Address of Issuer	7000 Shoreline Court Suite 350 San Francisco CALIFORNIA 94080
Phone	6504436209
Name of Person for Whose Account the Securities are To Be Sold	YUJIRO HATA
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	CEO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	J.P. Morgan Securities LLC 270 Park Avenue 10th Floor New York NY 10017	230316	8804981	96489484	10/06/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/06/2026	Stock Option Exercise	Issuer			230316	10/06/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The sales under this filing will include Cashless Option Exercises that will occur within 3 months from the date of this filing.
Date of Notice	10/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	07/07/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Yujiro Hata
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)